No benefit of selenium chemoprevention: The Eastern Collaborative Oncology Group (ECOG) conducted an intergroup randomized double-blind phase III clinical study in which 1522 patients with stage I NSCLC who had undergone surgical resection were given selenium yeast or placebo, with a median follow-up of more than 4 years. There was no significant difference between the two groups. What is the long-term benefit of neoadjuvant chemotherapy? A French study with a median follow-up of 13.8 years in 355 patients with surgically resectable NSCLC showed that 2 cycles of neoadjuvant chemotherapy with mitomycin + isocyclophosphamide + cisplatin (2 cycles of postoperative adjuvant therapy for those who were effective) did not significantly improve patient OS compared to surgery alone, but resulted in a stable survival benefit of 8% over 10 years, with multivariate analysis suggesting a long-term benefit. Gefitinib adjuvant therapy did not improve survival: The 4.7-year follow-up of the NCIC CTG BR.19 study showed that in 503 patients with post-resection stage IB to IIIA NSCLC, 2 years of gefitinib adjuvant therapy versus placebo. There was no significant disease-free survival (DFS) or OS benefit with treatment, and KRAS and EGFR replication had no prognostic or efficacy predictive value for gefitinib treatment.